Architectural rendering of the Merck Bioscience Production Center being established in Daejeon. Provided by Daejeon City,
,
, ‘German life science pioneer Merck Life Science (Merck) is investing 430 billion won to build a bio-process raw material production factory in Daejeon to supply the entire Asia-Pacific region.’,
,
, ‘On the 29th, Merck held a ground-breaking ceremony for the bioscience production center in Daejeon International Science Business Belt hub district, with Mayor Lee Chang-woo of Daejeon and Jung In-gyo, Director-General of Trade Negotiations, Ministry of Industry, attending the event. Merck plans to build a 43,000-square-meter production center in Guryong-dong, Yuseong-gu, the hub district of the International Science Business Belt by the end of 2026. The bioscience production center that Merck is building is a facility that produces raw materials used in bio-processes. Once the center is completed, it will support the development, clinical trials, and manufacturing of biopharmaceutical processes for pharmaceutical and bio-tech companies throughout the Asia-Pacific region.’,
,
, ‘Established in 1668, Merck is a global leader in healthcare, life sciences, and electronics industries, with a history of more than 350 years of innovation. With over 63,000 employees worldwide, the company operates 13 production and research facilities in South Korea employing 1,730 people. Daejeon has been making efforts to attract Merck’s production facilities since 2022 and signed a trilateral memorandum of understanding with the Ministry of Industry last May regarding investment cooperation in production facilities. Daejeon city explained that Merck’s investment in the Daejeon production center is the largest investment the company has made in the Asia-Pacific region.’,
,
, ‘Speaking at the ground-breaking ceremony, Matthias Heinzel, CEO of Merck, stated, “In Korea, there are many institutions that perform at an excellent level in the development, manufacturing, and service of biopharmaceuticals,” adding, “Korea is the most suitable country to realize the future that Merck aims for in the Asia-Pacific region, and the newly established bioscience production center will provide momentum to further activate the life sciences industry in Korea and across the Asia-Pacific region.”‘,
,
, ‘Daejeon city expects that the establishment of Merck’s production center will be an opportunity to create jobs and drive the development of the bio-industry. Merck plans to create over 300 new jobs in the Daejeon area by 2028. Mayor Lee Chang-woo stated, “The meeting of outstanding professionals and companies in Daejeon and Merck will be the beginning of a global bio-hub that surpasses Boston in the United States,” expressing expectations that Daejeon will leap forward as a central hub leading the development of the domestic pharmaceutical and bio-industry through the construction of Merck’s production center.\n’